In the Middle East and Africa pharmaceutical industry, there were 12 M&A deals announced in Q1 2024, worth a total value of $2.5bn, according to GlobalData’s Deals Database. The $2.2bn acquisition of Ambrx Biopharma by Johnson & Johnson was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q1 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Middle East and Africa increased by 150% in Q1 2024 compared with the previous quarter’s total of $1bn and rose by 2025% as compared to Q1 2023. Related deal volume increased by 50% in Q1 2024 versus the previous quarter and was 20% higher than in Q1 2023.
The top-ranked financial advisors supporting these M&A deals in Middle East and Africa in Q1 2024 were C.H. Stirling; Cantor Fitzgerald; Lazard with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Middle East and Africa in Q1 2024 were Meitar Law Offices; Centerview Partners; Cravath, Swaine & Moore with 2, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q1 2024 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.